4.7 Review

Nasal nanovaccines

Journal

INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 530, Issue 1-2, Pages 128-138

Publisher

ELSEVIER
DOI: 10.1016/j.ijpharm.2017.07.012

Keywords

Nanoparticles; Nasal vaccines; Vaccine delivery; NALT

Funding

  1. People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme FP7 under REA grant [607690]

Ask authors/readers for more resources

Nasal administration of vaccines is convenient for the potential stimulation of mucosal and systemic immune protection. Moreover the easy accessibility of the intranasal route renders it optimal for pandemic vaccination. Nanoparticles have been identified as ideal delivery systems and adjuvants for vaccine application. Heterogeneous protocols have been used for animal studies. This complicates the understanding of the formulation influence on the immune response and the comparison of the different nanoparticles approaches developed. Moreover anatomical and immunological differences between rodents and humans provide an additional hurdle in the rational development of nasal nanovaccines. This review will give a comprehensive expertise of the state of the art in nasal nanovaccines in animals and humans focusing on the nanomaterial used. (C) 2017 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available